|
Name |
16-O-sulfo-18-norisopimar-7-en-4alpha,16-diol
|
Molecular Formula | C19H32O5S | |
IUPAC Name* |
2-[(2S,4aS,4bR,8R,8aR)-8-hydroxy-2,4b,8-trimethyl-3,4,4a,5,6,7,8a,9-octahydro-1H-phenanthren-2-yl]ethyl hydrogen sulfate
|
|
SMILES |
C[C@@]1(CC[C@H]2C(=CC[C@@H]3[C@@]2(CCC[C@@]3(C)O)C)C1)CCOS(=O)(=O)O
|
|
InChI |
InChI=1S/C19H32O5S/c1-17(11-12-24-25(21,22)23)10-7-15-14(13-17)5-6-16-18(15,2)8-4-9-19(16,3)20/h5,15-16,20H,4,6-13H2,1-3H3,(H,21,22,23)/t15-,16+,17+,18+,19+/m0/s1
|
|
InChIKey |
MGAAHPXIGWJLPX-UURKPOQGSA-N
|
|
Synonyms |
16-O-sulfo-18-norisopimar-7-en-4alpha,16-diol; Sulfuric acid 2-[(1R)-1alpha-hydroxy-1,4abeta,7-trimethyl-1,2,3,4,4a,4balpha,5,6,7,8,10,10aalpha-dodecahydrophenanthrene-7alpha-yl]ethyl ester
|
|
CAS | NA | |
PubChem CID | 102357825 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 372.5 | ALogp: | 3.3 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 92.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 25 | QED Weighted: | 0.559 |
Caco-2 Permeability: | -5.04 | MDCK Permeability: | 0.00002100 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.053 | 20% Bioavailability (F20%): | 1 |
30% Bioavailability (F30%): | 0.6 |
Blood-Brain-Barrier Penetration (BBB): | 0.086 | Plasma Protein Binding (PPB): | 93.16% |
Volume Distribution (VD): | 1.154 | Fu: | 3.05% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.853 |
CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.785 |
CYP2C9-inhibitor: | 0.083 | CYP2C9-substrate: | 0.451 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.117 |
CYP3A4-inhibitor: | 0.086 | CYP3A4-substrate: | 0.049 |
Clearance (CL): | 2.809 | Half-life (T1/2): | 0.157 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.439 |
Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.025 |
Rat Oral Acute Toxicity: | 0.014 | Maximum Recommended Daily Dose: | 0.898 |
Skin Sensitization: | 0.732 | Carcinogencity: | 0.44 |
Eye Corrosion: | 0.363 | Eye Irritation: | 0.841 |
Respiratory Toxicity: | 0.981 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003257 | 0.614 | D01CKY | 0.269 | ||||
ENC005747 | 0.560 | D0Z1XD | 0.265 | ||||
ENC005750 | 0.485 | D0Q6NZ | 0.264 | ||||
ENC005748 | 0.478 | D0L2LS | 0.255 | ||||
ENC004729 | 0.477 | D0U3GL | 0.252 | ||||
ENC005749 | 0.436 | D0IX6I | 0.252 | ||||
ENC005751 | 0.396 | D02CNR | 0.250 | ||||
ENC001070 | 0.382 | D08QKJ | 0.248 | ||||
ENC002918 | 0.365 | D0I2SD | 0.248 | ||||
ENC002923 | 0.353 | D0X4RS | 0.246 |